cancer treatment

Perspective Therapeutics will present at two major investor conferences in April 2026, highlighting its alpha-emitting radiopharmaceutical pipeline for oncology.

Avastin market projected to grow from $7.82B in 2025 to $11.27B by 2030 at 7.5% CAGR, driven by cancer prevalence and biosimilar expansion.

Proleukin market projected to grow 6.1% annually to $1.68M by 2030, driven by rising cancer prevalence and expanded indications. Iovance Biotherapeutics strengthens position via 2023 acquisition.

ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.

ImmunityBio ($IBRX) shares plunged 21% after FDA warning over false Anktiva efficacy claims, erasing $2 billion in market value and triggering securities litigation.

Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.

ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.

Class action lawsuit filed against ImmunityBio for allegedly making false statements about cancer treatment Anktiva. FDA issued warning letter; stock fell 21% after disclosure.

Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.

Regeneron commits $150M through 2036 to Science Talent Search, awarding $1.8M to 40 finalists in STEM fields.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

MacroGenics to participate in four major healthcare investor conferences in March 2026, with management presenting on pipeline developments and business operations.